We studied telomere length in 32 CML patients who discontinued imatinib after achieving complete molecular remission and 32 age-sex-matched controls. The relative telomere length (RTL) was determined by q-PCR as the telomere to single copy gene (36B4) ratio normalized to a reference sample (K-562 DNA). Age-corrected RTL (acRTL) was also obtained. The 36-month probability of treatment-free remission (TFR) was 59.4 %. TFR patients showed shorter acRTL compared to relapsed (mean ± SD = 0.01 ± 0.14 vs 0.20 ± 0.21; p = 0.01). TFR was significantly higher in CML patients with acRTL ≤0.09 (78.9 vs 30.8 %, p = 0.002). CML stem cells harboring longer telomeres possibly maintain a proliferative potential after treatment discontinuation.
|Titolo:||Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients|
|Data di pubblicazione:||2016|
|Tipologia:||1.1 Articolo in rivista|
File in questo prodotto:
|Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients.pdf||versione post-print||Open Access Visualizza/Apri|